PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Ketoconazole

Drugs in development · updated 30 October 2026

Ketoconazole: clinical trials and development status

Other names and codes: Xolegel, Extina, Nizoral Anti-Dandruff, Nizoral

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 18 November 2014

As of 30 October 2026 Ketoconazole is in 6 active clinical trials (recruiting or ongoing, phases I–III) for 5 diseases. The most advanced phase is II.

6Active trials
IIMost advanced phase
5Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Ketoconazole and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Prostatic NeoplasmsII1NCT00859781
Brain NeoplasmsEarly I1NCT03763396
GlioblastomaEarly I1NCT07585851
GliomaEarly I1NCT03763396
NeoplasmEarly I1NCT03763396

Everything on Ketoconazole

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch